Douglas VanOort, the company's Chairman and CEO, commented, "Development of this software is a result of our commitment to offer innovative solutions and uncompromising quality for cancer testing. This innovation resulted from our licensing agreement with Health Discovery Corp, which provides NeoGenomics the exclusive worldwide rights to use SVM technology for all types of laboratory developed tests in hematopoietic and solid tumor cancers. We expect SVM technology will help us to automate certain manual testing processes, provide more accurate results for those tests that were previously dependent on subjective interpretations, and increase the productivity of our lab operations. To our knowledge, we are the first laboratory in the world to use SVM technology to assist in reading and interpreting ALK FISH data."Dr. Maher Albitar, the Company's Chief Medical Officer and Director of Research and Development, commented, "The science around using pattern recognition and computer-aided algorithms has improved significantly in the past few years. Our use of algorithms to interpret FISH digital data is just one step in a series of planned activities to adapt the SVM technology to cancer genetics testing. We believe these types of algorithms will be instrumental in helping to answer complex clinical questions and reducing the dependence on subjective interpretations."
NeoGenomics Develops And Implements Proprietary Method For Automating And Interpreting Fluorescence In-Situ Hybridization Test Data
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.